

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(formerly known as Genor Biopharma Holdings Limited)

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

CHANGE OF COMPANY NAME AND STOCK SHORT NAME

References are made to the circular of the Company dated 5 December 2025 (the “**Circular**”) and the announcement of the Company dated 30 December 2025 (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcement.

CHANGE OF COMPANY NAME

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Edding Genor Group Holdings Limited (the “**Company**”) is pleased to announce that subsequent to the approval of the Shareholders by passing a special resolution in relation to the Proposed Change of Company Name at the EGM, the certificate of incorporation on change of name was issued by the Registry of Companies in the Cayman Islands, certifying that the name of the Company has been changed from “Genor Biopharma Holdings Limited” to “Edding Genor Group Holdings Limited”, and the dual foreign name of the Company in Chinese has been changed from “嘉和生物藥業(開曼)控股有限公司” to “亿腾嘉和醫藥集團有限公司”, each with effect from 9:00 a.m. on 30 December 2025 (Hong Kong time).

The certificate of registration of alteration of name of registered non-Hong Kong company was issued by the Registrar of Companies in Hong Kong on 27 January 2026 confirming the registration of the Company’s new English and Chinese names of “Edding Genor Group Holdings Limited” and “亿腾嘉和醫藥集團有限公司” respectively in Hong Kong under Part 16 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong).

CHANGE OF STOCK SHORT NAME

The Board hereby announces that the stock short name for trading in the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) will be changed from “GENOR” to “EDDING GENOR” in English and from “嘉和生物” to “億騰嘉和” in Chinese with effect from 9:00 a.m. on 6 February 2026 in order to align with the Company’s current English name and dual foreign name in Chinese, better reflect the business of the Enlarged Group as well as relationship between the Company and the Controlling Shareholders following the Merger Closing. The English and Chinese names of the Company remain as “Edding Genor Group Holdings Limited” and “亿腾嘉和醫藥集團有限公司” respectively, and the stock code of the Company on the Stock Exchange remains as “6998”.

The change of stock short name, English name and dual foreign name in Chinese of the Company will not affect any rights of the existing shareholders of the Company.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 3 February 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Ms. Zhai Jing as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.